Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion

Immune-mediated inflammatory diseases (IMIDs) of the joints, gut and skin are treated with inhibitors of inflammatory cytokines. These cytokines are involved in the pathogenesis of coronavirus disease 2019 (COVID-19). Investigating anti-SARS-CoV-2 antibody responses in IMIDs we observe a reduced inc...

Descripción completa

Detalles Bibliográficos
Autores principales: Simon, David, Tascilar, Koray, Krönke, Gerhard, Kleyer, Arnd, Zaiss, Mario M., Heppt, Franz, Meder, Christine, Atreya, Raja, Klenske, Entcho, Dietrich, Peter, Abdullah, Abdullah, Kliem, Thorsten, Corte, Giulia, Morf, Harriet, Leppkes, Moritz, Kremer, Andreas E., Ramming, Andreas, Pachowsky, Milena, Schuch, Florian, Ronneberger, Monika, Kleinert, Stefan, Maier, Clara, Hueber, Axel J., Manger, Karin, Manger, Bernhard, Berking, Carola, Tenbusch, Matthias, Überla, Klaus, Sticherling, Michael, Neurath, Markus F., Schett, Georg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7382482/
https://www.ncbi.nlm.nih.gov/pubmed/32709909
http://dx.doi.org/10.1038/s41467-020-17703-6
Descripción
Sumario:Immune-mediated inflammatory diseases (IMIDs) of the joints, gut and skin are treated with inhibitors of inflammatory cytokines. These cytokines are involved in the pathogenesis of coronavirus disease 2019 (COVID-19). Investigating anti-SARS-CoV-2 antibody responses in IMIDs we observe a reduced incidence of SARS-CoV-2 seroconversion in IMID patients treated with cytokine inhibitors compared to patients receiving no such inhibitors and two healthy control populations, despite similar social exposure. Hence, cytokine inhibitors seem to at least partially protect from SARS-CoV-2 infection.

Ejemplares similares